APOPTOTIC AND PROLIFERATIVE ACTIVITY IN OVARIAN BENIGN,BORDERLINE AND MALIGNANT TUMORS

被引:0
|
作者
刘爱军
陈乐真
颜婉嫦
邱玮璇
赵昀
张雅贤
机构
关键词
Ki-67; M30; topoisomerase IIα; ovarian epithelial tumor;
D O I
暂无
中图分类号
R730.2 [肿瘤病理学、病因学];
学科分类号
100214 ;
摘要
Objective.To determine the apoptotic and proliferative activities in various ovarian epithelial tumors.Methods.Formalin-fixed,paraffin-embedded tissues of 86ovarian epithelial tu mors,including 52adenocarcino-mas,23borderline tumors and 11cystadenomas,were retrieved.Apoptoti c(AI )and proliferative(PI )index were estimated using the monoclonal antibodies:M30,Ki-67and Ki-S1in t hese tumors.Quantitative assess-ment of AI and PI was estimated by calc ulating the percentage of positive c ells among no less than 1000tumor cells.Results.Statistically significant differe nce in AI was found between benign and borderline tumors or carcino-mas(P=0.028,0.001,respectively).Significant differences in PI,as a ssessed by both Ki-67and topo IIα,were demonstrated between carcinom as and benign or borderline tumors(both P<0.001).Benign tumors had both low PI and AI;borderline tumors had lower PI but higher AI,while aden ocarcinomas had both high prolifera-tive and high apoptotic rates.Among borderline tumors,serous tumors had significantly lower AI and higher PI than mucinous ones.Conclusions.The results suggest that apoptotic a nd proliferative activities play im portant roles in the pathogene-sis and development of ovarian borderline and malignant tumors.The high apoptotic rate in borderline tumor m ay explain its relatively indolent beh avior while the high proliferative r ate in carcinomas tends to explain its aggres-sive behavior.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 50 条
  • [1] BORDERLINE OVARIAN TUMORS - ARE THEY BENIGN OR MALIGNANT?
    Lazarou, Anastasia
    Fotopoulou, Christina
    Coumbos, Alexandra
    Sehouli, Jalid
    Vasiljeva, Jekaterina
    Braicu, Ioana
    Burger, Heinz
    Kuehn, Wolfgang
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6257 - 6257
  • [2] Comparison of benign, borderline, and malignant mucinous ovarian tumors
    Yamamoto, Y.
    Kunimi, Y.
    Wakikawa, A.
    Ueno, A.
    Nagai, R.
    Komatsu, J.
    Minami, S.
    Hayashi, K.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 751 - 754
  • [3] Methylation profile in benign, borderline and malignant ovarian tumors
    K. F. Tam
    V. W. S. Liu
    S. S. Liu
    P. C. K. Tsang
    A. N. Y. Cheung
    A. M. W. Yip
    H. Y. S. Ngan
    [J]. Journal of Cancer Research and Clinical Oncology, 2007, 133 : 331 - 341
  • [4] Methylation profile in benign, borderline and malignant ovarian tumors
    Tam, K. F.
    Liu, V. W. S.
    Liu, S. S.
    Tsang, P. C. K.
    Cheung, A. N. Y.
    Yip, A. M. W.
    Ngan, H. Y. S.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (05) : 331 - 341
  • [5] Preservation of fertility in surgery of benign and borderline malignant ovarian tumors
    Guillaume, A.
    Pirrello, O.
    [J]. JOURNAL OF VISCERAL SURGERY, 2018, 155 : S17 - S21
  • [6] The predictive role of thrombocytosis in benign, borderline and malignant ovarian tumors
    Abdulrahman, Ganiy Opeyemi, Jr.
    Das, Nagindra
    Singh, Kerryn Lutchman
    [J]. PLATELETS, 2020, 31 (06) : 795 - 800
  • [7] Benign ovarian tumors and borderline tumors
    Pfleiderer, A
    [J]. GYNAKOLOGE, 2002, 35 (07): : 689 - 701
  • [8] u-PA expression in benign, borderline and malignant ovarian tumors
    Kiziridou, AD
    Toliou, T
    Stefanou, D
    Agnantis, N
    [J]. ANTICANCER RESEARCH, 2002, 22 (2A) : 985 - 990
  • [9] Expression of human telomerase subunits in ovarian malignant borderline and benign tumors
    Kyo, S
    Kanaya, T
    Takakura, M
    Tanaka, M
    Yamashita, A
    Inoue, H
    Inoue, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (06) : 804 - 809
  • [10] Differentiation of Borderline Epithelial Ovarian Tumors from Benign and Malignant Epithelial Ovarian Tumors by MRI Scoring
    Babaoglu, Seyma
    Atas, Abdullah Enes
    Kerimoglu, Ulku
    Iyisoy, Mehmet Sinan
    Kilinc, Fahriye
    [J]. CURRENT MEDICAL IMAGING, 2024, 20